• NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) has a Return on Invested Capital (ROIC) of -44.65%, significantly lower than its Weighted Average Cost of Capital (WACC) of 5.65%.
• ProKidney Corp. (PROK) demonstrates more efficient capital utilization with a positive ROIC of 16.10% against a WACC of 10.21%.
• Peers like Nuvalent, Inc. (NUVL) and PepGen Inc. (PEPG) also face challenges in generating sufficient returns on their invested capital.

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is a clinical-stage pharmaceutical company focused on developing transformative therapies for cardiovascular diseases. The company is currently facing challenges in capital efficiency, as indicated by its financial metrics. In the competitive landscape, NewAmsterdam Pharma's peers include companies like ProKidney Corp., Nuvalent, Inc., PepGen Inc., Tyra Biosciences, Inc., and HilleVax, Inc.

NewAmsterdam Pharma's Return on Invested Capital (ROIC) is -44.65%, which is significantly lower than its Weighted Average Cost of Capital (WACC) of 5.65%. This results in a ROIC to WACC ratio of -7.90, suggesting that the company is not generating returns that exceed its cost of capital. This indicates inefficiencies in capital utilization or challenges in its current business operations.

In comparison, ProKidney Corp. (PROK) demonstrates a positive ROIC of 16.10% against a WACC of 10.21%, resulting in a ROIC to WACC ratio of 1.58. This indicates that ProKidney is efficiently utilizing its capital and generating returns that exceed its cost of capital, suggesting potential for growth and profitability.

Other peers like Nuvalent, Inc. (NUVL) and PepGen Inc. (PEPG) also show negative ROICs of -21.92% and -68.85%, respectively, which are below their WACCs. This indicates similar challenges in generating sufficient returns on their invested capital, which is common in clinical-stage companies due to high R&D costs and uncertain outcomes.

Tyra Biosciences, Inc. (TYRA) and HilleVax, Inc. (HLVX) also face negative ROICs of -30.30% and -75.39%, respectively, with ROIC to WACC ratios of -3.24 and -11.44. These figures highlight the ongoing challenges in the sector, where companies are investing heavily in research and development with the hope of future profitability.